II 

Calendar No. 330 

110TH CONGRESS 

1ST SESSION S. 898 

To amend the Public Health Service Act to fund breakthroughs in Alzheimer’s 

disease research while providing more help to caregivers and increasing 

public education about prevention. 

IN THE SENATE OF THE UNITED STATES 

MARCH 15, 2007 

Ms. MIKULSKI (for herself, Mr. BOND, Mrs. CLINTON, Ms. COLLINS, Mr. 

MENENDEZ, Mr. DODD, Mr. KOHL, Mr. ISAKSON, Mrs. BOXER, Mr. 

BAYH, Mr. BROWN, Mr. COLEMAN, Mr. DURBIN, Mr. REED, Mr. CARPER, Mr. LUGAR, Mr. SANDERS, Ms. KLOBUCHAR, Mr. BURR, Mrs. MURRAY, Mr. SALAZAR, Mr. LAUTENBERG, and Mrs. LINCOLN) introduced 

the following bill; which was read twice and referred to the Committee 

on Health, Education, Labor, and Pensions 

AUGUST 3, 2007 

Reported by Mr. KENNEDY, with an amendment and an amendment to the 

title 

[Strike out all after the enacting clause and insert the part printed in italic] 

A BILL 

To amend the Public Health Service Act to fund breakthroughs in Alzheimer’s disease research while providing 

more help to caregivers and increasing public education 

about prevention. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

mstockstill on PROD1PC66 with BILLS

2 

•S 898 RS

1 SECTION 1. SHORT TITLE. 

2 This Act may be cited as the ‘‘Alzheimer’s Break3 through Act of 2007’’. 

4 SEC. 2. FINDINGS. 

5 Congress makes the following findings: 

6 (1) Alzheimer’s disease is a disorder that de7 stroys cells in the brain. The disease is the leading 

8 cause of dementia, a condition that involves gradual 

9 memory loss, decline in the ability to perform rou10 tine tasks, disorientation, difficulty in learning, loss 

11 of language skills, impairment of judgment, and per12 sonality changes. As the disease progresses, people 

13 with Alzheimer’s disease become unable to care for 

14 themselves. The loss of brain cells eventually leads 

15 to the failure of other systems in the body. 

16 (2) An estimated 4,500,000 Americans have 

17 Alzheimer’s disease and 1 in 10 individuals have a 

18 family member with the disease. By 2050, the num19 ber of individuals with the disease could range from 

20 13,000,000 to 16,000,000 unless science finds a way 

21 to prevent or cure the disease. 

22 (3) One in 10 people over the age of 65, and 

23 nearly half of those over the age of 85 have Alz24 heimer’s disease. Younger people also get the dis25 ease. 

mstockstill on PROD1PC66 with BILLS

3 

•S 898 RS

1 (4) The Alzheimer’s disease process may begin 

2 in the brain as many as 20 years before the symp3 toms of Alzheimer’s disease appear. An individual 

4 will live an average of 8 years and as many as 20 

5 once the symptoms of Alzheimer’s disease appear. 

6 (5) The average lifetime cost of care for an in7 dividual with Alzheimer’s disease is $170,000. 

8 (6) In 2005, Medicare alone spent 

9 $91,000,000,000 for the care of individuals with 

10 Alzheimer’s disease and this amount is projected to 

11 increase to $160,000,000,000 in 2010. 

12 (7) Ninety-five percent of Medicare beneficiaries 

13 with Alzheimer’s disease have one or more other 

14 chronic conditions that are common in the elderly, 

15 coronary heart disease (30 percent), congestive heart 

16 failure (28 percent), diabetes (21 percent), and 

17 chronic obstructive pulmonary disease (17 percent). 

18 (8) Seven in 10 individuals with Alzheimer’s 

19 disease live at home. While almost 75 percent of 

20 home care is provided by family and friends, the av21 erage annual cost of paid care for people with Alz22 heimer’s disease at home is $19,000 per year. Al23 most all families pay this cost out of pocket. 

24 (9) Half of all nursing home residents have Alz25 heimer’s disease or a related disorder. The average 

mstockstill on PROD1PC66 with BILLS

4 

•S 898 RS

1 annual cost of Alzheimer’s disease nursing home 

2 care is more than $70,000. Medicaid pays half of 

3 the total nursing home bill and helps 2 out of 3 resi4 dents pay for their care. Medicaid expenditures for 

5 nursing home care for people with Alzheimer’s dis6 ease are estimated to increase from $21,000,000,000 

7 in 2005 to $24,000,000,000 in 2010. 

8 (10) In fiscal year 2007, the Federal Govern9 ment will spend an estimated $642,000,000 on Alz10 heimer’s disease research. If the United States 

11 achieves its research goals (preventing the onset of 

12 Alzheimer’s disease in those at risk and treating and 

13 delaying progression of the disease in those who 

14 have symptoms), annual Medicare savings would be 

15 $51,000,000,000 by 2015 and $88,000,000,000 by 

16 2020. Annual Medicaid savings would be 

17 $10,000,000,000 in 2015 and $17,000,000,000 by 

18 2020 and the projected number of cases of Alz19 heimer’s disease can be reduced by 40 percent by 

20 the middle of the century. 

21 (11) An analysis by the Montefiore Medical 

22 Center and the Albert Einstein College of Medicine 

23 estimated that the annual value of the informal care 

24 system is $306,000,000,000. Family caregiving 

mstockstill on PROD1PC66 with BILLS

5 

•S 898 RS

1 comes at enormous physical, emotional, and financial 

2 sacrifice, putting the whole system at risk. 

3 (12) One in 8 Alzheimer’s disease caregivers be4 comes ill or injured as a direct result of caregiving. 

5 One in 3 uses medication for problems related to 

6 caregiving. Older caregivers are 3 times more likely 

7 to become clinically depressed than others in their 

8 age group. 

9 (13) Elderly spouses strained by caregiving are 

10 63 percent more likely to die during a given 4-year 

11 period than other spouses their age. 

12 (14) Almost 3 of 4 caregivers are women. One 

13 in 3 has children or grandchildren under the age of 

14 18 living at home. Caregiving leaves them less time 

15 for other family members and they are much more 

16 likely to report family conflicts because of their 

17 caregiving role. 

18 (15) Most Alzheimer’s disease caregivers work 

19 outside the home before beginning their caregiving 

20 careers, but caregiving forces them to miss work, cut 

21 back to part-time, take less demanding jobs, choose 

22 early retirement, or give up work altogether. As a 

23 result, in 2002, Alzheimer’s disease cost American 

24 business an estimated $36,500,000,000 in lost promstockstill on PROD1PC66 with BILLS

6 

•S 898 RS

1 ductivity, as well as an additional $24,600,000,000 

2 in business contributions to the total cost of care. 

3 TITLE I—INCREASING THE FED4 ERAL COMMITMENT TO ALZ5 HEIMER’S RESEARCH 

6 SEC. 101. DOUBLING NIH FUNDING FOR ALZHEIMER’S DIS7 EASE RESEARCH. 

8 (a) IN GENERAL.—For the purpose of conducting 

9 and supporting research on Alzheimer’s disease (including 

10 related activities under subpart 5 of part C of title IV of 

11 the Public Health Service Act (42 U.S.C. 285e et seq.) 

12 there is authorized to be appropriated $1,300,000,000 for 

13 fiscal year 2008, and such sums as may be necessary for 

14 each of fiscal years 2009 through 2012. 

15 (b) AGING PROCESS REGARDING WOMEN.—Section 

16 445H(b) of the Public Health Service Act (42 U.S.C. 

17 285e–10(b)) is amended by striking ‘‘2003’’ and inserting 

18 ‘‘2012’’. 

19 (c) CLINICAL RESEARCH AND TRAINING AWARDS.— 

20 Section 445I(d) of the Public Health Service Act (42 

21 U.S.C. 285e–10a(d)) is amended by striking ‘‘2005’’ and 

22 inserting ‘‘2012’’. 

23 SEC. 102. PRIORITY TO ALZHEIMER’S DISEASE RESEARCH. 

24 Section 443 of the Public Health Service Act (42 

25 U.S.C. 285e) is amended— 

mstockstill on PROD1PC66 with BILLS

7 

•S 898 RS

1 (1) by striking ‘‘The general’’ and inserting 

2 ‘‘(a) IN GENERAL.—The general’’; and 

3 (2) by adding at the end the following: 

4 ‘‘(b) PRIORITIES.—The Director of the Institute 

5 shall, in expending amounts appropriated under this sub6 part, give priority to conducting and supporting Alz7 heimer’s disease research.’’. 

8 SEC. 103. ALZHEIMER’S DISEASE PREVENTION INITIATIVE. 

9 Section 443 of the Public Health Service Act (42 

10 U.S.C. 285e), as amended by section 102, is further 

11 amended by adding at the end the following: 

12 ‘‘(c) PREVENTION TRIALS.—The Director of the In13 stitute shall increase the emphasis on the need to conduct 

14 Alzheimer’s disease prevention trials within the National 

15 Institutes of Health. 

16 ‘‘(d) NEUROSCIENCE INITIATIVE.—The Director of 

17 the Institute shall ensure that Alzheimer’s disease is main18 tained as a high priority for the existing neuroscience ini19 tiative.’’. 

20 SEC. 104. ALZHEIMER’S DISEASE CLINICAL RESEARCH. 

21 (a) CLINICAL RESEARCH.—Subpart 5 of part C of 

22 title IV of the Public Health Service Act (42 U.S.C. 285e 

23 et seq.) is amended by adding at the end the following: 

mstockstill on PROD1PC66 with BILLS

8 

•S 898 RS

1 ‘‘SEC. 445J. ALZHEIMER’S DISEASE CLINICAL RESEARCH. 

2 ‘‘(a) IN GENERAL.—The Director of the Institute, 

3 pursuant to subsections (d) and (e) of section 444, shall 

4 conduct and support cooperative clinical research regard5 ing Alzheimer’s disease. Such research shall include— 

6 ‘‘(1) investigating therapies, interventions, and 

7 agents to detect, treat, slow the progression of, or 

8 prevent Alzheimer’s disease; 

9 ‘‘(2) enhancing the national infrastructure for 

10 the conduct of clinical trials; 

11 ‘‘(3) developing and testing novel approaches to 

12 the design and analysis of such trials; 

13 ‘‘(4) facilitating the enrollment of patients for 

14 such trials, including patients from diverse popu15 lations; 

16 ‘‘(5) developing improved diagnostics and 

17 means of patient assessment for Alzheimer’s disease; 

18 ‘‘(6) the conduct of clinical trials on potential 

19 therapies, including readily available compounds 

20 such as herbal remedies and other alternative treat21 ments; 

22 ‘‘(7) research to develop better methods of early 

23 diagnosis, including the use of current imaging tech24 niques; and 

25 ‘‘(8) other research as determined appropriate 

26 by the Director of the Institute, the Alzheimer’s Dismstockstill on PROD1PC66 with BILLS

9 

•S 898 RS

1 ease Centers and Alzheimer’s Disease Research Cen2 ters established under section 445. 

3 ‘‘(b) EARLY DIAGNOSIS AND DETECTION RE4 SEARCH.— 

5 ‘‘(1) IN GENERAL.—The Director of the Insti6 tute, in consultation with the directors of other rel7 evant institutes and centers of the National Insti8 tutes of Health, shall conduct, or make grants for 

9 the conduct of, research related to the early detec10 tion, diagnosis, and prevention of Alzheimer’s dis11 ease and of mild cognitive impairment or other po12 tential precursors to Alzheimer’s disease. 

13 ‘‘(2) EVALUATION.—The research described in 

14 paragraph (1) may include the evaluation of diag15 nostic tests and imaging techniques. 

16 ‘‘(3) STUDY.—Not later than 1 year after the 

17 date of enactment of this section, the Director of the 

18 Institute, in cooperation with the heads of other rel19 evant Federal agencies, shall conduct a study, and 

20 submit to Congress a report, to estimate the number 

21 of individuals with early-onset Alzheimer’s disease 

22 (those diagnosed before the age of 65) and related 

23 dementias in the United States, the causes of early24 onset dementia, and the unique problems faced by 

mstockstill on PROD1PC66 with BILLS

10 

•S 898 RS

1 such individuals, including problems accessing gov2 ernment services. 

3 ‘‘(c) VASCULAR DISEASE.—The Director of the Insti4 tute, in consultation with the directors of other relevant 

5 institutes and centers of the National Institutes of Health, 

6 shall conduct, or make grants for the conduct of, research 

7 related to the relationship of vascular disease and Alz8 heimer’s disease, including clinical trials to determine 

9 whether drugs developed to prevent cerebrovascular dis10 ease can prevent the onset or progression of Alzheimer’s 

11 disease. 

12 ‘‘(d) TREATMENTS AND PREVENTION.—The Director 

13 of the Institute shall place special emphasis on expediting 

14 the translation of research findings under this section into 

15 effective treatments and prevention strategies for at-risk 

16 individuals. 

17 ‘‘(e) NATIONAL ALZHEIMER’S COORDINATING CEN18 TER.—The Director of the Institute may establish a Na19 tional Alzheimer’s Coordinating Center to facilitate col20 laborative research among the Alzheimer’s Disease Cen21 ters and Alzheimer’s Disease Research Centers established 

22 under section 445.’’. 

23 (b) ALZHEIMER’S DISEASE CENTERS.—Section 

24 445(a)(1) of the Public Health Service Act (42 U.S.C. 

25 285e–2(a)(1)) is amended by inserting ‘‘, and outcome 

mstockstill on PROD1PC66 with BILLS

11 

•S 898 RS

1 measures and disease management’’ after ‘‘treatment 

2 methods’’. 

3 SEC. 105. RESEARCH ON ALZHEIMER’S DISEASE 

4 CAREGIVING. 

5 Section 445C of the Public Health Service Act (42 

6 U.S.C. 285e–5) is amended— 

7 (1) by striking ‘‘SEC. 445C. (a)’’ and inserting 

8 the following: 

9 ‘‘SEC. 445C. RESEARCH ON ALZHEIMER’S DISEASE SERV10 ICES AND CAREGIVING. 

11 ‘‘(a) SERVICES RESEARCH.—’’; 

12 (2) by striking subsections (b), (c), and (e); 

13 (3) by inserting after subsection (a) the fol14 lowing: 

15 ‘‘(b) INTERVENTIONS RESEARCH.—The Director 

16 shall, in collaboration with the directors of the other rel17 evant institutes and centers of the National Institutes of 

18 Health, conduct, or make grants for the conduct of, clin19 ical, social, and behavioral research related to interven20 tions designed to help caregivers of patients with Alz21 heimer’s disease and related disorders and improve patient 

22 outcomes.’’; and 

23 (4) in subsection (d) by striking ‘‘(d) the Direc24 tor’’ and inserting ‘‘(c) MODEL CURRICULA AND

25 TECHNIQUES.—The Director’’. 

mstockstill on PROD1PC66 with BILLS

12 

•S 898 RS

1 SEC. 106. NATIONAL SUMMIT ON ALZHEIMER’S DISEASE. 

2 (a) IN GENERAL.—Not later than 3 years after the 

3 date of enactment of this Act, and every 3 years there4 after, the Secretary of Health and Human Services (re5 ferred to in this section as the ‘‘Secretary’’) shall convene 

6 a summit of researchers, representatives of academic insti7 tutions, Federal and State policymakers, public health 

8 professionals, and representatives of voluntary health 

9 agencies to provide a detailed overview of current research 

10 activities at the National Institutes of Health, as well as 

11 to discuss and solicit input related to potential areas of 

12 collaboration between the National Institutes of Health 

13 and other Federal health agencies, including the Centers 

14 for Disease Control and Prevention, the Administration on 

15 Aging, the Agency for Healthcare Research and Quality, 

16 and the Health Resources and Services Administration, 

17 related to research, prevention, and treatment of Alz18 heimer’s disease. 

19 (b) FOCUS AREAS.—The summit convened under 

20 subsection (a) shall focus on— 

21 (1) a broad range of Alzheimer’s disease re22 search activities relating to biomedical research, pre23 vention research, and caregiving issues; 

24 (2) clinical research for the development and 

25 evaluation of new treatments for the disease; 

mstockstill on PROD1PC66 with BILLS

13 

•S 898 RS

1 (3) translational research on evidence-based and 

2 cost-effective best practices in the treatment and 

3 prevention of the disease; 

4 (4) information and education programs for 

5 health care professionals and the public relating to 

6 the disease; 

7 (5) priorities among the programs and activities 

8 of the various Federal agencies regarding such dis9 eases; and 

10 (6) challenges and opportunities for scientists, 

11 clinicians, patients, and voluntary organizations re12 lating to the disease. 

13 (c) REPORT.—Not later than 180 days after the date 

14 on which the National Summit on Alzheimer’s Disease is 

15 convened under subsection (a), the Director of National 

16 Institutes of Health shall prepare and submit to the ap17 propriate committees of Congress a report that includes 

18 a summary of the proceedings of the summit and a de19 scription of Alzheimer’s research, education, and other ac20 tivities that are conducted or supported through the na21 tional research institutes. 

22 (d) PUBLIC INFORMATION.—The Secretary shall 

23 make readily available to the public information about the 

24 research, education, and other activities relating to Alzmstockstill on PROD1PC66 with BILLS

14 

•S 898 RS

1 heimer’s disease and other related dementias, conducted 

2 or supported by the National Institutes of Health. 

3 TITLE II—PUBLIC HEALTH PRO4 MOTION AND PREVENTION 

5 OF ALZHEIMER’S DISEASE 

6 SEC. 201. ENHANCING PUBLIC HEALTH ACTIVITIES RE7 LATED TO COGNITIVE HEALTH, ALZHEIMER’S 

8 DISEASE, AND OTHER DEMENTIA’S. 

9 Part P of title III of the Public Health Service Act 

10 (42 U.S.C. 280g et seq.) is amended by adding at the end 

11 the following: 

12 ‘‘SEC. 399R. ALZHEIMER’S DISEASE PUBLIC EDUCATION 

13 CAMPAIGN. 

14 ‘‘(a) IN GENERAL.—The Secretary, acting through 

15 the Director of the Centers for Disease Control and Pre16 vention, shall directly or through grants, cooperative 

17 agreements, or contracts to eligible entities, conduct, sup18 port, and promote the coordination of research, investiga19 tions, demonstrations, training, and studies relating to the 

20 control, prevention, and surveillance of the risk factors as21 sociated with cognitive health, Alzheimer’s disease, and 

22 other dementia’s, and seek early recognition and interven23 tion in the course of Alzheimer’s disease and other demen24 tias. 

mstockstill on PROD1PC66 with BILLS

15 

•S 898 RS

1 ‘‘(b) CERTAIN ACTIVITIES.—Activities under sub2 section (a) shall include— 

3 ‘‘(1) providing support for the dissemination 

4 and implementation of the Roadmap to Maintaining 

5 Cognitive Health to effectively mobilize the public 

6 health community into action; 

7 ‘‘(2) the development of coordinated public edu8 cation programs, services, and demonstrations which 

9 are designed to increase general awareness of cog10 nitive function and promote a brain healthy lifestyle; 

11 ‘‘(3) the development of targeted communica12 tion strategies and tools to educate health profes13 sionals and service providers about the early recogni14 tion, diagnosis, care, and management of Alz15 heimer’s disease and dementia, and to provide con16 sumers with information about interventions, prod17 ucts, and services that promote cognitive health and 

18 assist consumers in maintaining current under19 standing about cognitive health based on the best 

20 science available; and 

21 ‘‘(4) provide support for the collection, publica22 tion, and analysis of data on the prevalence and inci23 dence of cognitive health, Alzheimer’s disease, and 

24 other dementias, and the evaluation of existing pop25 ulation-based surveillance systems (such as the Bemstockstill on PROD1PC66 with BILLS

16 

•S 898 RS

1 havioral Risk Factors Surveillance Survey (BRFFS) 

2 and the National Health Interview Survey (NHIS)) 

3 to identify limitations that exist in the area of cog4 nitive health, and if necessary, the development of a 

5 surveillance system for cognitive decline, including 

6 Alzheimer’s disease and dementia. 

7 ‘‘(c) GRANTS.—The Secretary may award grants 

8 under this section— 

9 ‘‘(1) to State and local health agencies for the 

10 purpose of— 

11 ‘‘(A) coordinating activities related to cog12 nitive health, Alzheimer’s disease, and other de13 mentias with existing State-based health pro14 grams and community-based organizations; 

15 ‘‘(B) providing Alzheimer’s disease edu16 cation and training opportunities and programs 

17 for health professionals; and 

18 ‘‘(C) developing, testing, evaluating, and 

19 replicating effective Alzheimer’s disease inter20 vention programs to maintain or improve cog21 nitive health; and 

22 ‘‘(2) to nonprofit private health organizations 

23 with expertise in providing care and services to indi24 viduals with Alzheimer’s disease for the purpose 

25 of— 

mstockstill on PROD1PC66 with BILLS

17 

•S 898 RS

1 ‘‘(A) disseminating information to the pub2 lic; 

3 ‘‘(B) testing model intervention programs 

4 to improve cognitive health; and 

5 ‘‘(C) coordinating existing services with 

6 State-based health programs. 

7 ‘‘(d) AUTHORIZATION OF APPROPRIATIONS.—For the 

8 purpose of carrying out this section, there are authorized 

9 to be appropriated $15,000,000 for fiscal year 2008, and 

10 such sums as may be necessary for each of fiscal years 

11 2009 through 2012.’’. 

12 TITLE III—ASSISTANCE FOR 

13 CAREGIVERS 

14 SEC. 301. ALZHEIMER’S DISEASE CALL CENTER. 

15 Part P of title III of the Public Health Service Act 

16 (42 U.S.C. 280g et seq.), as amended by section 201, is 

17 further amended by adding at the end the following: 

18 ‘‘SEC. 399S. ALZHEIMER’S DISEASE CALL CENTER. 

19 ‘‘(a) IN GENERAL.—The Secretary, acting through 

20 the Administration on Aging, shall award a cooperative 

21 grant to a non-profit or community-based organization to 

22 support the establishment and operation of an Alzheimer’s 

23 Call Center that is accessible 24 hours a day, 7 days a 

24 week, to provide expert advice, care consultation, informamstockstill on PROD1PC66 with BILLS

18 

•S 898 RS

1 tion, and referrals nationwide at the national and local 

2 level regarding Alzheimer’s disease. 

3 ‘‘(b) ACTIVITIES.—The Alzheimer’s Call Center es4 tablished under subsection (a) shall— 

5 ‘‘(1) collaborate with the Administration on 

6 Aging in the development, modification, and execu7 tion of the Call Center’s work plan; 

8 ‘‘(2) assist the Administration on Aging in de9 veloping and sustaining collaborations between the 

10 Alzheimer’s Call Center, the Eldercare Locator, the 

11 grantees under the Alzheimer’s Demonstration Pro12 gram, and the Aging Network; 

13 ‘‘(3) provide a 24-hour a day, 7-days a week 

14 toll-free Call Center with trained professional staff 

15 who are available to provide care consultation and 

16 crisis intervention to individuals with Alzheimer’s 

17 disease and other dementias, their family and infor18 mal caregivers, and others as appropriate; 

19 ‘‘(4) be accessible by telephone through a single 

20 1–800 telephone number, website and e-mail ad21 dress; and 

22 ‘‘(5) evaluate the impact of the Call Center’s 

23 activities and services. 

24 ‘‘(c) MULTILINGUAL CAPACITY.—The Call Center es25 tablished under this section shall have a multilingual camstockstill on PROD1PC66 with BILLS

19 

•S 898 RS

1 pacity and shall respond to inquiries in at least 140 lan2 guages through its own bilingual staff and with the use 

3 of a language translation service. 

4 ‘‘(d) RESPONSE TO EMERGENCY AND ONGOING

5 NEEDS.—The Call Center established under this section 

6 shall collaborate with community-based organizations, in7 cluding non-profit agencies and organizations, to ensure 

8 local, on-the-ground capacity to respond to emergency and 

9 on-going needs of Alzheimer’s patients, their families, and 

10 informal caregivers. 

11 ‘‘(e) AUTHORIZATION OF APPROPRIATIONS.—For the 

12 purpose of carrying out this section, there are authorized 

13 to be appropriated $1,000,000 for fiscal year 2008, and 

14 such sums as may be necessary for each of fiscal years 

15 2009 through 2012.’’. 

16 SEC. 302. INNOVATIVE ALZHEIMER’S CARE STATE MATCH17 ING GRANT PROGRAM. 

18 (a) AUTHORIZATION OF APPROPRIATIONS.—Section 

19 398B(e) of the Public Health Service Act (42 U.S.C. 

20 280c–5(e)) is amended— 

21 (1) by striking ‘‘and such’’ and inserting 

22 ‘‘such’’; and 

23 (2) by inserting before the period the following: 

24 ‘‘, $25,000,000 for fiscal year 2008, and such sums 

mstockstill on PROD1PC66 with BILLS

20 

•S 898 RS

1 as may be necessary for each of fiscal years 2009 

2 through 2012’’. 

3 (b) PROGRAM EXPANSION.—Section 398(a) of the 

4 Public Health Service Act (42 U.S.C. 280c–3(a)) 

5 (1) in paragraph (2), by inserting after ‘‘other 

6 respite care’’ the following: ‘‘and care consultation 

7 including assessment of needs, assistance with plan8 ning and problem solving and providing supportive 

9 listening’’; 

10 (2) in paragraph (3), by striking ‘‘; and’’ and 

11 inserting the following: ‘‘and individuals in frontier 

12 areas (as defined as areas with 6 or fewer people per 

13 square mile or areas in which it takes people at least 

14 60 minutes or 60 miles to reach a market or service 

15 area);’’; 

16 (3) in paragraph (4), by striking the period at 

17 the end and inserting a semicolon; and 

18 (4) by adding at the end the following: 

19 ‘‘(5) to encourage grantees under this section to 

20 coordinate activities with other State officials admin21 istering efforts to promote long-term care options 

22 that enable older individuals to receive long-term 

23 care in home- and community-based settings, in a 

24 manner responsive to the needs and preferences of 

25 older individuals and their family caregivers; 

mstockstill on PROD1PC66 with BILLS

21 

•S 898 RS

1 ‘‘(6) to encourage grantees under this section 

2 to— 

3 ‘‘(A) engage in activities that support early 

4 detection and diagnosis of Alzheimer’s disease 

5 and related dementia; 

6 ‘‘(B) provide training to medical personnel 

7 including hospital staff, emergency room per8 sonnel, home health care workers and physician 

9 office staff, rehabilitation services providers, 

10 and caregivers about how Alzheimer’s can affect 

11 behavior and impede communication in medical 

12 and community settings; 

13 ‘‘(C) develop guidelines to provide the med14 ical community with up-to-date information 

15 about the best methods of care for individuals 

16 with Alzheimer’s disease; 

17 ‘‘(D) inform community physicians about 

18 available resources to assist them in detecting 

19 and managing Alzheimer’s; and 

20 ‘‘(E) raise awareness among community 

21 physicians about the availability of community22 based organizations which can assist individuals 

23 with Alzheimer’s and their caregivers; 

24 ‘‘(7) to encourage grantees under this section to 

25 engage in activities that use findings from evidencemstockstill on PROD1PC66 with BILLS

22 

•S 898 RS

1 based research on service models and techniques to 

2 support individuals with Alzheimer’s disease and 

3 their caregivers; and 

4 ‘‘(8) to encourage grantees under this section to 

5 incorporate best practices for effectively serving indi6 viduals with Alzheimer’s disease in community-based 

7 settings into ongoing State systems change and 

8 long-term care activities.’’. 

9 SECTION 1. SHORT TITLE. 

10 This Act may be cited as the ‘‘Alzheimer’s Break11 through Act of 2007’’. 

12 SEC. 2. FINDINGS. 

13 Congress makes the following findings: 

14 (1) Alzheimer’s disease is a disorder that de15 stroys cells in the brain. The disease is the leading 

16 cause of dementia, a condition that involves gradual 

17 memory loss, decline in the ability to perform routine 

18 tasks, disorientation, difficulty in learning, loss of 

19 language skills, impairment of judgment, and person20 ality changes. As the disease progresses, people with 

21 Alzheimer’s disease become unable to care for them22 selves. The loss of brain cells eventually leads to the 

23 failure of other systems in the body. 

24 (2) An estimated 4,500,000 Americans have Alz25 heimer’s disease and 1 in 10 individuals have a fammstockstill on PROD1PC66 with BILLS

23 

•S 898 RS

1 ily member with the disease. By 2050, the number of 

2 individuals with the disease could range from 

3 13,000,000 to 16,000,000 unless science finds a way 

4 to prevent or cure the disease. 

5 (3) One in 10 people over the age of 65, and 

6 nearly half of those over the age of 85 have Alz7 heimer’s disease. Younger people also get the disease. 

8 (4) The Alzheimer’s disease process may begin in 

9 the brain as many as 20 years before the symptoms 

10 of Alzheimer’s disease appear. An individual will live 

11 an average of 8 years and as many as 20 once the 

12 symptoms of Alzheimer’s disease appear. 

13 (5) The average lifetime cost of care for an indi14 vidual with Alzheimer’s disease is $170,000. 

15 (6) In 2005, Medicare alone spent 

16 $91,000,000,000 for the care of individuals with Alz17 heimer’s disease and this amount is projected to in18 crease to $160,000,000,000 in 2010. 

19 (7) Ninety-five percent of Medicare beneficiaries 

20 with Alzheimer’s disease have one or more other 

21 chronic conditions that are common in the elderly, 

22 coronary heart disease (30 percent), congestive heart 

23 failure (28 percent), diabetes (21 percent), and chron24 ic obstructive pulmonary disease (17 percent). 

mstockstill on PROD1PC66 with BILLS

24 

•S 898 RS

1 (8) Seven in 10 individuals with Alzheimer’s 

2 disease live at home. While almost 75 percent of home 

3 care is provided by family and friends, the average 

4 annual cost of paid care for people with Alzheimer’s 

5 disease at home is $19,000 per year. Almost all fami6 lies pay this cost out of pocket. 

7 (9) Half of all nursing home residents have Alz8 heimer’s disease or a related disorder. The average 

9 annual cost of Alzheimer’s disease nursing home care 

10 is more than $70,000. Medicaid pays half of the total 

11 nursing home bill and helps 2 out of 3 residents pay 

12 for their care. Medicaid expenditures for nursing 

13 home care for people with Alzheimer’s disease are esti14 mated to increase from $21,000,000,000 in 2005 to 

15 $24,000,000,000 in 2010. 

16 (10) In fiscal year 2007, the Federal Government 

17 will spend an estimated $642,000,000 on Alzheimer’s 

18 disease research. If the United States achieves its re19 search goals (preventing the onset of Alzheimer’s dis20 ease in those at risk and treating and delaying pro21 gression of the disease in those who have symptoms), 

22 annual Medicare savings would be $51,000,000,000 

23 by 2015 and $88,000,000,000 by 2020. Annual Med24 icaid savings would be $10,000,000,000 in 2015 and 

25 $17,000,000,000 by 2020 and the projected number of 

mstockstill on PROD1PC66 with BILLS

25 

•S 898 RS

1 cases of Alzheimer’s disease would be reduced by 40 

2 percent by the middle of the century. 

3 (11) An analysis by the Montefiore Medical Cen4 ter and the Albert Einstein College of Medicine esti5 mated that the annual value of the informal care sys6 tem is $306,000,000,000. Family caregiving comes at 

7 enormous physical, emotional, and financial sacrifice, 

8 putting the whole system at risk. 

9 (12) One in 8 Alzheimer’s disease caregivers be10 comes ill or injured as a direct result of caregiving. 

11 One in 3 uses medication for problems related to 

12 caregiving. Older caregivers are 3 times more likely 

13 to become clinically depressed than others in their age 

14 group. 

15 (13) Elderly spouses strained by caregiving are 

16 63 percent more likely to die during a given 4-year 

17 period than other spouses their age. 

18 (14) Almost 3 of 4 caregivers are women. One in 

19 3 has children or grandchildren under the age of 18 

20 living at home. Caregiving leaves them less time for 

21 other family members and they are much more likely 

22 to report family conflicts because of their caregiving 

23 role. 

24 (15) Most Alzheimer’s disease caregivers work 

25 outside the home before beginning their caregiving camstockstill on PROD1PC66 with BILLS

26 

•S 898 RS

1 reers, but caregiving forces them to miss work, cut 

2 back to part-time, take less demanding jobs, choose 

3 early retirement, or give up work altogether. As a re4 sult, in 2002, Alzheimer’s disease cost American busi5 ness an estimated $36,500,000,000 in lost produc6 tivity, as well as an additional $24,600,000,000 in 

7 business contributions to the total cost of care. 

8 TITLE I—INCREASING THE FED9 ERAL COMMITMENT TO ALZ10 HEIMER’S RESEARCH 

11 SEC. 101. INCREASE IN NIH FUNDING FOR ALZHEIMER’S 

12 DISEASE RESEARCH. 

13 For the purpose of conducting and supporting research 

14 on Alzheimer’s disease, cognitive health, and related dis15 orders (including related activities under subpart 5 of part 

16 C of title IV of the Public Health Service Act (42 U.S.C. 

17 285e et seq.) there is authorized to be appropriated 

18 $780,000,000 for fiscal year 2008, $910,000,000 for fiscal 

19 year 2009, $1,040,000,000 for fiscal year 2010, 

20 $1,170,000,000 for fiscal year 2011, and $1,300,000,000 for 

21 fiscal year 2012. 

22 SEC. 102. PRIORITY TO ALZHEIMER’S DISEASE RESEARCH. 

23 Section 444(d) of the Public Health Service Act (42 

24 U.S.C. 285e–1(d)) is amended by adding at the end the fol25 lowing: ‘‘The Director of the Institute shall continue to 

mstockstill on PROD1PC66 with BILLS

27 

•S 898 RS

1 make research related to Alzheimer’s Disease, cognitive 

2 health, and related disorders’, a priority within the Insti3 tute’s activities consistent with the peer-review process.’’. 

4 SEC. 103. ALZHEIMER’S DISEASE PREVENTION INITIATIVE. 

5 Section 444 of the Public Health Service Act (42 

6 U.S.C. 285e–1), as amended by section 102, is further 

7 amended by adding at the end the following: 

8 ‘‘(e) PREVENTION TRIALS.—The Director of the Insti9 tute, shall increase the emphasis on the need to conduct Alz10 heimer’s disease, cognitive health, and related disorders pre11 vention trials within the National Institutes of Health. 

12 ‘‘(f) NEUROSCIENCE INITIATIVE.—The Director of the 

13 Institute, shall ensure that Alzheimer’s disease, cognitive 

14 health, and related disorders is maintained as a high pri15 ority for the existing neuroscience initiative.’’. 

16 SEC. 104. ALZHEIMER’S DISEASE CLINICAL RESEARCH. 

17 (a) CLINICAL RESEARCH.—Subpart 5 of part C of title 

18 IV of the Public Health Service Act (42 U.S.C. 285e et seq.) 

19 is amended by adding at the end the following: 

20 ‘‘SEC. 445J. ALZHEIMER’S DISEASE CLINICAL RESEARCH. 

21 ‘‘(a) IN GENERAL.—The Secretary, acting through the 

22 Director of the Institute, pursuant to subsection (d) of sec23 tion 444, shall, consistent with the peer-review and priority 

24 setting process of the Institute, conduct and support cooper25 ative clinical research regarding Alzheimer’s disease, cogmstockstill on PROD1PC66 with BILLS

28 

•S 898 RS

1 nitive health, and related disorders. Such research may in2 clude— 

3 ‘‘(1) investigating therapies, interventions, and 

4 agents to detect, treat, slow the progression of, or pre5 vent Alzheimer’s disease; 

6 ‘‘(2) enhancing the national infrastructure for 

7 the conduct of clinical trials; 

8 ‘‘(3) developing and testing novel approaches to 

9 the design and analysis of such trials; 

10 ‘‘(4) facilitating the enrollment of patients for 

11 such trials, including patients from diverse popu12 lations; 

13 ‘‘(5) developing improved diagnostics and means 

14 of patient assessment for Alzheimer’s disease; 

15 ‘‘(6) the conduct of clinical trials on potential 

16 therapies, including readily available compounds such 

17 as herbal remedies and other alternative treatments; 

18 ‘‘(7) research to develop better methods of early 

19 diagnosis, including the use of current imaging tech20 niques; 

21 ‘‘(8) enhance research currently being done on 

22 minorities and health disparities; and 

23 ‘‘(9) other research as determined appropriate by 

24 the Director of the Institute, the Alzheimer’s Disease 

mstockstill on PROD1PC66 with BILLS

29 

•S 898 RS

1 Centers and Alzheimer’s Disease Research Centers es2 tablished under section 445. 

3 ‘‘(b) EARLY DIAGNOSIS AND DETECTION RE4 SEARCH.— 

5 ‘‘(1) IN GENERAL.—The Secretary, acting 

6 through the Director of the Institute, in consultation 

7 with the directors of other relevant institutes and cen8 ters of the National Institutes of Health, shall con9 duct, or make grants for the conduct of, research re10 lated to the early detection, diagnosis, and prevention 

11 of Alzheimer’s disease and of mild cognitive impair12 ment or other potential precursors to Alzheimer’s dis13 ease. 

14 ‘‘(2) EVALUATION.—The research described in 

15 paragraph (1) may include the evaluation of diag16 nostic tests and imaging techniques. 

17 ‘‘(3) STUDY ON THE PREVALENCE AND CAUSES

18 OF EARLY ONSET DEMENTIA.—The Director of the In19 stitute is encouraged to explore the feasibility and sci20 entific opportunities in research regarding the preva21 lence and causes of early onset dementia (diagnosed 

22 before the age of 65). 

23 ‘‘(c) VASCULAR DISEASE.—The Secretary, acting 

24 through the Director of the Institute, in consultation with 

25 the directors of other relevant institutes and centers of the 

mstockstill on PROD1PC66 with BILLS

30 

•S 898 RS

1 National Institutes of Health, are strongly encouraged to 

2 conduct or make grants for the conduct of research related 

3 to the relationship of vascular disease and Alzheimer’s dis4 ease and related disorders, including clinical trials to deter5 mine whether drugs developed to prevent cerebrovascular 

6 disease can prevent the onset or progression of Alzheimer’s 

7 disease. 

8 ‘‘(d) TREATMENTS AND PREVENTION.—The Secretary, 

9 acting through the Director of the Institute, shall place spe10 cial emphasis on expediting the translation of research find11 ings under this section into effective treatments and preven12 tion strategies for at-risk individuals. 

13 ‘‘(e) NATIONAL ALZHEIMER’S COORDINATING CEN14 TER.—The Secretary, acting through the Director of the In15 stitute, may establish a National Alzheimer’s Coordinating 

16 Center to facilitate collaborative research among the Alz17 heimer’s Disease Centers and Alzheimer’s Disease Research 

18 Centers established under section 445.’’. 

19 (b) ALZHEIMER’S DISEASE CENTERS.—Section 

20 445(a)(1) of the Public Health Service Act (42 U.S.C. 285e– 

21 2(a)(1)) is amended by inserting ‘‘, and outcome measures 

22 and disease management’’ after ‘‘treatment methods’’. 

mstockstill on PROD1PC66 with BILLS

31 

•S 898 RS

1 SEC. 105. RESEARCH ON ALZHEIMER’S DISEASE 

2 CAREGIVING. 

3 Section 445C of the Public Health Service Act (42 

4 U.S.C. 285e–5) is amended— 

5 (1) by striking ‘‘SEC. 445C. (a)’’ and inserting 

6 the following: 

7 ‘‘SEC. 445C. RESEARCH ON ALZHEIMER’S DISEASE SERV8 ICES AND CAREGIVING. 

9 ‘‘(a) SERVICES RESEARCH.—’’; 

10 (2) by striking subsections (b), (c), and (e); 

11 (3) by inserting after subsection (a) the fol12 lowing: 

13 ‘‘(b) INTERVENTIONS RESEARCH.—The Secretary, act14 ing through the Director, shall, in collaboration with the 

15 directors of the other relevant institutes and centers of the 

16 National Institutes of Health, conduct, or make grants for 

17 the conduct of, clinical, social, and behavioral research re18 lated to interventions designed to help caregivers of patients 

19 with Alzheimer’s disease and related disorders and improve 

20 patient outcomes.’’; and 

21 (4) in subsection (d) by striking ‘‘(d) the Direc22 tor’’ and inserting ‘‘(c) MODEL CURRICULA AND

23 TECHNIQUES.—The Director’’. 

mstockstill on PROD1PC66 with BILLS

32 

•S 898 RS

1 SEC. 106. NATIONAL SUMMIT ON ALZHEIMER’S DISEASE 

2 AND RELATED DISORDERS. 

3 (a) IN GENERAL.—Not later than 3 years after the 

4 date of enactment of this Act, and every 3 years thereafter, 

5 the Secretary of Health and Human Services (referred to 

6 in this section as the ‘‘Secretary’’) shall convene a summit 

7 of researchers, representatives of academic institutions, Fed8 eral and State policy makers, public health professionals, 

9 community health organizations, and representatives of vol10 untary health organizations to provide a detailed overview 

11 of current research activities at the National Institutes of 

12 Health, as well as to discuss and solicit input related to 

13 potential areas of collaboration between the National Insti14 tutes of Health and other Federal health agencies, including 

15 the Centers for Disease Control and Prevention, the Admin16 istration on Aging, the Agency for Healthcare Research and 

17 Quality, and the Health Resources and Services Adminis18 tration, related to research, prevention, and treatment of 

19 Alzheimer’s disease. 

20 (b) FOCUS AREAS.—The summit convened under sub21 section (a) shall focus on— 

22 (1) a broad range of Alzheimer’s disease research 

23 activities relating to breakthroughs in biomedical re24 search, prevention research, and caregiving issues; 

25 (2) clinical research for the development and 

26 evaluation of new treatments for Alzheimer’s disease; 

mstockstill on PROD1PC66 with BILLS

33 

•S 898 RS

1 (3) translational research on evidence-based and 

2 cost-effective best practices in the treatment and pre3 vention of Alzheimer’s disease; 

4 (4) international research and activities relating 

5 to breakthroughs in prevention, diagnosis, and treat6 ment of Alzheimer’s disease; 

7 (5) advances in complimentary and alternative 

8 medicine related to Alzheimer’s disease; 

9 (6) information and education programs for 

10 health care professionals and the public relating to 

11 Alzheimer’s disease; 

12 (7) priorities among the programs and activities 

13 of the various Federal agencies related to Alzheimer’s 

14 disease; and 

15 (8) challenges and opportunities for scientists, 

16 clinicians, patients, and voluntary organizations re17 lating to Alzheimer’s disease. 

18 (c) REPORT.—Not later than 180 days after the date 

19 on which the National Summit on Alzheimer’s Disease is 

20 convened under subsection (a), the Secretary, acting 

21 through the Director of National Institutes of Health, shall 

22 prepare and submit to the appropriate committees of Con23 gress a report that includes a summary of the proceedings 

24 of the summit and a description of Alzheimer’s research, 

mstockstill on PROD1PC66 with BILLS

34 

•S 898 RS

1 education, and other activities that are conducted or sup2 ported through the national research institutes. 

3 (d) PUBLIC INFORMATION.—The Secretary shall make 

4 readily available to the public information about the re5 search, education, and other activities relating to Alz6 heimer’s disease and other related dementias, conducted or 

7 supported by the National Institutes of Health. 

8 TITLE II—ENHANCED PUBLIC 

9 HEALTH ACTIVITIES RELATED 

10 TO COGNITIVE HEALTH, ALZ11 HEIMER’S DISEASE AND 

12 OTHER DEMENTIAS 

13 SEC. 201. ENHANCED PUBLIC HEALTH ACTIVITIES RELATED 

14 TO COGNITIVE HEALTH, ALZHEIMER’S DIS15 EASE, AND OTHER DEMENTIAS. 

16 Part P of title III of the Public Health Service Act 

17 (42 U.S.C. 280g et seq.) is amended by adding at the end 

18 the following: 

19 ‘‘SEC. 399R. ALZHEIMER’S DISEASE PUBLIC EDUCATION 

20 AWARENESS PROGRAM. 

21 ‘‘(a) IN GENERAL.—The Secretary, acting through the 

22 Director of the Centers for Disease Control and Prevention, 

23 shall directly or through grants, cooperative agreements, or 

24 contracts to eligible entities, conduct, support, and promote 

25 the coordination of research, investigations, demonstrations, 

mstockstill on PROD1PC66 with BILLS

35 

•S 898 RS

1 training, and studies relating to the control, prevention, 

2 and surveillance of the risk factors associated with cognitive 

3 health, Alzheimer’s disease, and related disorders, and seek 

4 early recognition and intervention in the course of Alz5 heimer’s disease and related disorders. 

6 ‘‘(b) CERTAIN ACTIVITIES.—Activities under sub7 section (a) may include— 

8 ‘‘(1) providing support for the dissemination 

9 and implementation of the Roadmap to Maintaining 

10 Cognitive Health to effectively mobilize the public 

11 health community into action; 

12 ‘‘(2) the development of coordinated public edu13 cation programs, services, and demonstrations which 

14 are designed to increase general awareness of cog15 nitive function and promote a brain healthy lifestyle; 

16 ‘‘(3) the development of targeted communication 

17 strategies and tools to educate health professionals 

18 and service providers about the early recognition, di19 agnosis, care, and management of Alzheimer’s disease 

20 and related disorders, and to provide consumers with 

21 information about interventions, products, and serv22 ices that promote cognitive health and assist con23 sumers in maintaining current understanding about 

24 cognitive health based on the best science available; 

25 and 

mstockstill on PROD1PC66 with BILLS

36 

•S 898 RS

1 ‘‘(4) provide support for the collection, publica2 tion, and analysis of data on the prevalence and inci3 dence of cognitive function, Alzheimer’s disease and 

4 related disorders, and the related public health bur5 den, and the evaluation of existing population-based 

6 surveillance systems (such as the Behavioral Risk 

7 Factors Surveillance Survey (BRFFS) and the Na8 tional Health Interview Survey (NHIS)) to identify 

9 limitations that exist in the area of cognitive health, 

10 and if necessary, the development of a surveillance 

11 system for cognitive decline, including Alzheimer’s 

12 disease and related disorders. 

13 ‘‘(c) GRANTS.—The Secretary may award grants 

14 under this section— 

15 ‘‘(1) to State and local health agencies and 

16 health organizations for the purpose of— 

17 ‘‘(A) coordinating activities related to Alz18 heimer’s disease, cognitive health, and related 

19 disorders with existing State-based health pro20 grams and community-based organizations; 

21 ‘‘(B) providing Alzheimer’s disease, cog22 nitive health, and related disorders education 

23 and training opportunities and programs for 

24 health professionals; and 

mstockstill on PROD1PC66 with BILLS

37 

•S 898 RS

1 ‘‘(C) developing, testing, evaluating, and 

2 replicating effective Alzheimer’s disease and re3 lated disorders intervention programs to main4 tain or improve cognitive health; and 

5 ‘‘(2) to nonprofit private health organizations 

6 with expertise in providing care and services to indi7 viduals with Alzheimer’s disease and related disorders 

8 for the purpose of— 

9 ‘‘(A) disseminating information to the pub10 lic; 

11 ‘‘(B) testing model intervention programs to 

12 improve cognitive health; and 

13 ‘‘(C) coordinating existing services with 

14 State-based health programs. 

15 ‘‘(d) AUTHORIZATION OF APPROPRIATIONS.—For the 

16 purpose of carrying out this section, there are authorized 

17 to be appropriated $3,000,000 for each of fiscal years 2008 

18 through 2012.’’. 

19 TITLE III—ASSISTANCE FOR 

20 CAREGIVERS 

21 SEC. 301. ALZHEIMER’S DISEASE CALL CENTER. 

22 Part P of title III of the Public Health Service Act 

23 (42 U.S.C. 280g et seq.), as amended by section 201, is fur24 ther amended by adding at the end the following: 

mstockstill on PROD1PC66 with BILLS

38 

•S 898 RS

1 ‘‘SEC. 399S. ALZHEIMER’S DISEASE CALL CENTER. 

2 ‘‘(a) IN GENERAL.—The Secretary, acting through the 

3 Administration on Aging, shall award a cooperative grant 

4 to a non-profit or community-based organization to support 

5 the establishment and operation of an Alzheimer’s Call Cen6 ter that is accessible 24 hours a day, 7 days a week, to 

7 provide expert advice, care consultation, information, and 

8 referrals nationwide at the national and local level regard9 ing Alzheimer’s disease and related disorders. 

10 ‘‘(b) ACTIVITIES.—The Alzheimer’s Call Center estab11 lished under subsection (a) shall— 

12 ‘‘(1) collaborate with the Administration on 

13 Aging in the development, modification, and execu14 tion of the Call Center’s work plan; 

15 ‘‘(2) assist the Administration on Aging in de16 veloping and sustaining collaborations between the 

17 Alzheimer’s Call Center, the Eldercare Locator, the 

18 grantees under the Alzheimer’s Demonstration Pro19 gram, and the Aging Network; 

20 ‘‘(3) provide a 24-hour a day, 7-days a week toll21 free Call Center with trained professional staff who 

22 are available to provide care consultation and crisis 

23 intervention to individuals with Alzheimer’s disease 

24 and other dementias, their family and informal care25 givers, and others as appropriate; 

mstockstill on PROD1PC66 with BILLS

39 

•S 898 RS

1 ‘‘(4) be accessible by telephone through a single 

2 1–800 telephone number, website and e-mail address; 

3 and 

4 ‘‘(5) evaluate the impact of the Call Center’s ac5 tivities and services. 

6 ‘‘(c) MULTILINGUAL CAPACITY.—The Call Center es7 tablished under this section shall have a multilingual ca8 pacity and shall respond to inquiries in at least 140 lan9 guages through its own bilingual staff and with the use of 

10 a language translation service. 

11 ‘‘(d) RESPONSE TO EMERGENCY AND ONGOING

12 NEEDS.—The Call Center established under this section 

13 shall collaborate with community-based organizations, in14 cluding non-profit agencies and organizations, to ensure 

15 local, on-the-ground capacity to respond to emergency and 

16 on-going needs of Alzheimer’s patients, their families, and 

17 informal caregivers. 

18 ‘‘(e) AUTHORIZATION OF APPROPRIATIONS.—For the 

19 purpose of carrying out this section, there are authorized 

20 to be appropriated $1,000,000 for fiscal year 2008, and 

21 such sums as may be necessary for each of fiscal years 2009 

22 through 2012.’’. 

mstockstill on PROD1PC66 with BILLS

40 

•S 898 RS

1 SEC. 302. INNOVATIVE ALZHEIMER’S CARE STATE MATCH2 ING GRANT PROGRAM. 

3 (a) AUTHORIZATION OF APPROPRIATIONS.—Section 

4 398B(e) of the Public Health Service Act (42 U.S.C. 280c– 

5 5(e)) is amended— 

6 (1) by striking ‘‘and such’’ and inserting ‘‘such’’; 

7 and 

8 (2) by inserting before the period the following: 

9 ‘‘, and $20,000,000 for each of fiscal years 2008 

10 through 2012’’. 

11 (b) PROGRAM EXPANSION.—Section 398(a) of the Pub12 lic Health Service Act (42 U.S.C. 280c–3(a)) 

13 (1) in paragraph (2), by inserting after ‘‘other 

14 respite care’’ the following: ‘‘and care consultation in15 cluding assessment of needs, assistance with planning 

16 and problem solving and providing supportive listen17 ing’’; 

18 (2) in paragraph (3), by striking ‘‘; and’’ and 

19 inserting the following: ‘‘and individuals in frontier 

20 areas (as defined as areas with 6 or fewer people per 

21 square mile or areas in which it takes people at least 

22 60 minutes or 60 miles to reach a market or service 

23 area);’’; 

24 (3) in paragraph (4), by striking the period at 

25 the end and inserting a semicolon; and 

26 (4) by adding at the end the following: 

mstockstill on PROD1PC66 with BILLS

41 

•S 898 RS

1 ‘‘(5) to encourage grantees under this section to 

2 coordinate activities with other State officials admin3 istering efforts to promote long-term care options that 

4 enable older individuals to receive long-term care in 

5 home- and community-based settings, in a manner re6 sponsive to the needs and preferences of older individ7 uals and their family caregivers; 

8 ‘‘(6) to encourage grantees under this section 

9 to— 

10 ‘‘(A) engage in activities that support early 

11 detection and diagnosis of Alzheimer’s disease 

12 and related disorders; 

13 ‘‘(B) provide training to medical personnel 

14 including hospital staff, emergency room per15 sonnel, home health care workers and physician 

16 office staff, rehabilitation services providers, and 

17 caregivers about how Alzheimer’s can affect be18 havior and impede communication in medical 

19 and community settings; 

20 ‘‘(C) develop guidelines to provide the med21 ical community with up-to-date information 

22 about the best methods of care for individuals 

23 with Alzheimer’s disease and related disorders; 

24 ‘‘(D) inform community physicians about 

25 available resources to assist them in detecting 

mstockstill on PROD1PC66 with BILLS

42 

•S 898 RS

1 and managing Alzheimer’s disease and related 

2 disorders; and 

3 ‘‘(E) raise awareness among community 

4 physicians about the availability of community5 based organizations which can assist individuals 

6 with Alzheimer’s disease and related disorders 

7 and their caregivers; 

8 ‘‘(7) to encourage grantees under this section to 

9 engage in activities that use findings from evidence10 based research on service models and techniques to 

11 support individuals with Alzheimer’s disease and re12 lated disorders and their caregivers; 

13 ‘‘(8) to encourage grantees under this section to 

14 incorporate best practices for effectively serving indi15 viduals with Alzheimer’s disease and related disorders 

16 in community-based settings into ongoing State sys17 tems change and long-term care activities; and 

18 ‘‘(9) to encourage grantees to coordinate with 

19 Aging and Disability Resource Centers or other single 

20 point of entry systems.’’. 

Amend the title so as to read: ‘‘A bill to amend the 

Public Health Service Act to fund breakthroughs in Alzheimer’s disease research while providing more help to 

caregivers and increasing public and provider awareness 

about steps that may be taken to respond rapidly to 

breakthroughs in prevention, early detection, and manmstockstill on PROD1PC66 with BILLS

43 

•S 898 RS

agement, about cognitive health, Alzheimer’s disease, and 

other dementias related to aging.’’. 

mstockstill on PROD1PC66 with BILLS

Calendar No. 330 

110TH CONGRESS 

1ST SESSION S. 898 

A BILL 

To amend the Public Health Service Act to fund 

creasing public education about prevention. while providing more help to caregivers and inbreakthroughs in Alzheimer’s disease research 

AUGUST 3, 2007 

Reported with an amendment and an amendment to the 

title 

mstockstill on PROD1PC66 with BILLS